Compounds for the treatment of inflammatory disorders and microbial diseases
View Patent ↗This invention relates to compounds of the Formulae (I)-(IX): or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-α or combinations thereof.
1. A compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein:
(i) each of R 1 and R 2 independently is hydrogen or alkyl;
(ii) R 3 and R 4 taken together with the nitrogen to which they shown attached is benzopyrrolyl;
wherein said benzopyrrolyl is substituted with one or two substituents, each substituent being independently selected from the group consisting of aryl and alkynyl;
wherein said aryl substituent is unsubstituted or is optionally substituted with one or two moieties selected independently from the group consisting of perhaloalkyl, halo, alkyl, alkoxy, cyano, perhaloalkoxy, and alkynyl moiety, wherein said alkynyl moiety is substituted with an aryl radical;
wherein said alkynyl substituent is substituted with an aryl moiety, wherein said aryl moiety is unsubstituted or optionally substituted with one to three radicals selected from the group consisting of perhaloalkyl, halo, alkyl, alkoxy, cyano, and perhaloalkoxy; and
(iii) R 5 and R 6 taken together with the nitrogen to which they shown attached is pyrrolodinyl;
wherein said pyrrolodinyl is unsubstituted or substituted with an aryl substituent;
wherein said aryl substituent is unsubstituted or substituted with one to three moieties independently selected from the group consisting of perhaloalkyl, halo, alkyl, alkoxy, cyano, and perhaloalkoxy.
2. The compound of claim 1 , wherein R 1 and R 2 are both hydrogen.
3. The compound according to claim 1 , wherein:
the aryl substituent of the benzopyrrolyl is substituted with an alkynyl moiety, wherein said alkynyl moiety is substituted with an aryl radical; and
the alkynyl substituent of the benzopyrrolyl comprising R 3 and R 4 is substituted with an aryl moiety.
4. The compound according to claim 3 , wherein the aryl substituent of the benzopyrrolyl is phenyl.
5. The compound according to claim 3 , wherein the aryl radical of the alkynyl moiety is phenyl.
6. The compound according to claim 1 , wherein said pyrrolodinyl is unsubstituted.
7. The compound according to claim 1 , wherein said pyrrolodinyl is substituted with an aryl substituent, wherein said aryl substituent is substituted with a halo moiety.
8. The compound according to claim 7 , wherein said aryl substituent is phenyl.
9. The compound according to claim 1 , wherein said aryl substituent of said benzopyrrollyl is unsubstituted or substituted with perhaloalkyl.
10. The compound according to claim 9 , wherein said aryl substituent is phenyl.
11. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
12. A pharmaceutical composition comprising as an active ingredient at least one compound of claim 1 , or a pharmaceutically acceptable salt thereof.
13. The pharmaceutical composition of claim 12 additionally comprising at least one pharmaceutically acceptable carrier.
14. A method of treating a condition or disease selected from the group consisting of rheumatoid arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, neovascular glaucoma, inflammatory bowel disease, multiple sclerosis and psoriasis in a subject, comprising: administering to the subject in need of such treatment a therapeutically effective amount of at least one compound of claim 1 , or a pharmaceutically acceptable salt thereof.